Lakeland PBS
❤ Donate
  • Home
  • Support
  • Watch Now
    • Livestream
    • Local Shows
    • Watch Online
    • Schedule
    • Our Channels
    • Webcam
  • Lakeland News
    • News Feed
    • Featured Segments
    • Watch a News Story
    • Watch a Sports Story
  • Shop
  • About
    • Contact Us
    • State Legacy Funding
    • Meetings & Public Filings
    • Education
    • Employment
  • ❤ DONATE

Pfizer Agrees to Let Other Companies Make Its COVID-19 Pill

Nick Ursini — Nov. 16 2021
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • More
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to print (Opens in new window)

LONDON (AP) — Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population.

In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population.

The deal excludes some large countries that have suffered devastating coronavirus outbreaks. For example, while a Brazilian drug company could get a license to make the pill for export to other countries, the medicine could not be made generically for use in Brazil.

Still, health officials said the fact that the deal was struck even before Pfizer’s pill has been authorized anywhere, could help to end the pandemic quicker.

“It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.

He estimated that other drugmakers would be able to start producing the pill within months, but acknowledged the agreement wouldn’t please everyone.

“We try to strike a very delicate balance between the interests of the (company), the sustainability required by generic producers and most importantly, the public health needs in lower and middle-income countries,” Burrone said.

Under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries and will waive royalties on sales in all countries covered by the agreement while COVID-19 remains a public health emergency.

Earlier this month, Pfizer said its pill cut the risk of hospitalization and death by nearly 90% in people with mild to moderate coronavirus infections. Independent experts recommended halting the company’s study based on its promising results.

Pfizer said it would ask the U.S. Food and Drug Administration and other regulators to authorize the pill as soon as possible.

Since the pandemic erupted last year, researchers worldwide have raced to develop a pill to treat COVID-19 that can be taken at home easily to ease symptoms, speed recovery and keep people out of the hospital. At the moment, most COVID-19 treatments must be delivered intravenously or by injection.

Britain authorized Merck’s COVID-19 pill earlier this month, and it is pending approval elsewhere. In a similar deal with the Medicines Patent Pool announced in October, Merck agreed to let other drugmakers make its COVID-19 pill, molnupiravir, available in 105 poorer countries.

Doctors Without Borders said it was “disheartened” that the Pfizer deal does not make the drug available to the entire world, noting that the agreement announced Tuesday also excludes countries including China, Argentina and Thailand.

“The world knows by now that access to COVID-19 medical tools needs to be guaranteed for everyone, everywhere, if we really want to control this pandemic,” said Yuanqiong Hu, a senior legal policy adviser at Doctors Without Borders.

The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes for wider production. A hub set up by the World Health Organization in South Africa intended to share messenger RNA vaccine recipes and technologies has not enticed a single pharmaceutical to join.

Fewer than 1% of Pfizer’s COVID-19 shots have gone to poorer countries.

Robbie Silverman of Oxfam America welcomed Pfizer’s agreement to let other makers produce its COVID antiviral, but he noted that billions would still be left without access, including to the company’s vaccine.

“This move also begs the important question: If Pfizer can share data and intellectual property on a medicine, why have they so far categorically refused to do so for their COVID vaccine?” Silverman said.

Lakeland News is member supported content. Please consider supporting Lakeland News today.

Donate Today
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • More
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to print (Opens in new window)

By — Nick Ursini

Related Posts

Brigid’s Pub in Bemidji Remains Busy Despite Shutdown from Fire Last Year

BSU Announces Major Layoffs in Response to Budget Deficits

Update: Bemidji State University to Enact Staff Layoffs

10 More People Charged in $250M Federal Food Program Fraud

  • Program Schedule

Get the free PBS Video App

roku
Apple TV
FireTV
AndroidTV
Google Play Store
Apple Store

Connect with Us

Watch Lakeland PBS Live Stream!

Contact Us

Directions
Submit an Event
Submit a Video or Photo
Problem with the Website
Need to contact us about something else? Please visit our contact us page for more options.

About Us

Lakeland PBS understands the media that people are exposed to make a significant impact on their lives. Our hope is that the six channels we broadcast along with our online presence provide people with media experiences that make a positive impact on their lives.

Lakeland PBS is where you want to be!

108 Grant Ave NE, Bemidji, MN 56601 | 800-292-0922
KAWE Public Profile | KAWB Public Profile | Cable Provider Channel List | Privacy Policy
Copyright © 2023 Lakeland PBS. All Right Reserved.

How would you like to show your support?

Monthly Contribution

One-Time Contribution

Thank-You Gift

I would like to select a thank-you gift

No Gift

Put 100% of my gift towards programming